| Cancer |
Public Current Cancer Trials
BLADDER
A phase I/II trial of combination of Paclitaxel and Trastuzumab with daily irradiation or Paclitaxel alone with daily irradiation following transurethral surgery for non-cystectomy candidates with muscle-invasive bladder cancer.
Click for Protocol Summary
A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer.
Bone Metastases
(Observational)
A prospective observational Multicenter Cohort Study to Assess the Incident of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment.
BRAIN
N0574 XRT ONLY
Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases.
RTOG 0834 - (Anaplastic Glioma)
Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic Glioma: The Catnon Intergroup Trial.
BREAST
SCCA 6628
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed by Bevacizumab and Erlotinib in Treating Patients With Metastatic Breast Cancer
Please Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumab given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In situ Resected by Lumpectomy.
SWOG 0800
A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel with or without Bevacizumab, either Preceded by or Followed by Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) plus Pegfilgrastim (Peg-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/NEU Negative Breast Cancer.
C40603
Randomized Phase II 2X2 factorial Trial of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in hormone Receptor-Poor/hER-2 negative Resectable Breast Cancer.
HLMCC 0806
(Adjuvant OR Neoadjuvant)
Phase II placebo-controlled trial of lisinopril and Coreg to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with trastuzumab (Herceptin).
NCIC CTG MA.32 & MA.32F
((T 1-3, NO-3, MO))
A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer. MA32F: Biobehavioral Mechanisms of Fatigue in Patients Treated on MA.32.
N0733 -ON HOLD 3-20-12
Phse II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane.
SWOG 1007
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
BREAST - Cont.
A Randomized Phase III Trial of Adjuvant Therapy Comparing
Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
NSABP B-49
A Phsae III Clinical trial comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.
Click for Protocol Summary
Cancer Related Fatigue
COGNITIVE-BREAST/LYMPHOMA
Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at pre-Treatment, Post-Treatment, and at Six Month Follow-Up.
GASTROINTESTINAL
CALGB 80702
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.
NSABP P-5
(Polyp Prevention Trial)
Statin Polyp prevention Trial in Patients with Resected Colon Cancer.
RTOG 0848
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
RTOG 1010
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
Click for Protocol Summary
RTOG 0436
A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery.
GOG 0249
A Phase III Trial of Pelvic radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma.
Please Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
GOG 0258
A Randomized Phase III Trial of Cisplatin and tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carconoma.
Please Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
S1201
A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer.
GENITOURINARY
SWOG 1014
Abiraterone Acetate Treatment for Prostate Cancer patients with a PSA of More than Four Following Initial Androgen Deprivation Therapy, Phase II.
SWOG 0925
A Randomized Phase II Study of Androgen Deprivation Combined with IMC-A12 Versus Androgen Deprivation Alone for Patients with New Hormone-Sensitive Metastatic Prostate Cancer.
RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer.
RTOG 0534
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy.
CALGB 90203
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer.
CALGB 70807
The Men's Eating and Living (MEAL) Study: A Randomized Trial of diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance.
SWOG 0931
Everest: Everolimus for Renal Cancer Ensuring Surgical Therapy, a Phase III Study
CALGB 90802
Randomized Phase III Trial comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing after Treatment with Tyrosine Kinase Inhibitors.
CALGB 90601
A randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in patients with advanced transitional cell carcinoma (TCC).
GYNECOLOGIC
RTOG 0724
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.
GOG 0262
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer.
Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
GOG 213
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC#704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian,Peritoneal Primary and Fallopian Tube Cancer.
Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
GOG 212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or XyotaxTM (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
GOG 0261
(CIRB): A Randomized Phase III Trial of Paclitaxel Plus Carboplatin versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal tumors) of the Uterus or Ovary.
Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
HEAD & NECK
Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.
LIVER
CALGB 80802
Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC).
ACCURAY ACC-HM-100.3
(Cyberknife)
International Phase II Study of Cyberknife for hepatic Metastases from Colorectal Cancer.
Contact:
Samantha Elliott
253-403-2319
LUNG
CALGB 140503
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2 Cm) Peripheral Non-Small Cell Lung Cancer.
U3-1287 (AMG888)
Randomizded, placebo-controlled, double-blind phase iB/2 study of U3-1287 (AMG888) in combination with erlotinib in EGFR treatment naive subjects with advanced non-small cell lung cancer who have progressed on at least one prior chemotherapy. Erlotinib and U3-1287 (AMG888) arre supplied by sponsor.
Click for Protocol Summary
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
ACCURAY-ACCL001.1
(Cyberknife)
A prospective Evaluation of Outcomes of Radiosurgical Treatment of Early Stage Non-Small Cell Lung Cancer.
Contact:
Samantha Elliott
253-403-2319
ECOG 5508
Randomized Phase III Study of Maintenance Therapy with Bevacizumab Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advance Non-Squamous NSCLC.
SWOG 0819
A Randomized Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without concurrent Cetuximab in patients with advanced non-small cell lung cancer.
ECOG 1505
A Phase III Randomized Trial of Adjuvant chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>4 cm) IIIA Non-Small Lung Cancer.
NCCTG N0923
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, after Standard Platinum Containing Induction Regimens of Cytoreductive Chemotherapy for Patients with Extensive Stage Small Cell Lung Carcinoma. NCI supplies NTX-010/placebo.
LYMPHOCYTIC LEUKEMIA
A Phase I/II Study of Fludarabine, Cyclophosphamide Rituximab, and Vorinostat Followed by Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
Contact:
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
PSOC 2301
A Phase II Study of Bexxar Consolidation in Patients with B-Cell Chronic Lymphocytic Leukemia Following Fludarabine and Rituximab Chemotherapy.
Click for Protocol Summary
Contact:
Diane Miller, RN, MN, AOCN
Phone: 253-403-5265
Pager: 253-305-1859
Fax: 253-403-2391
Christine Goetz:
253-403-7193;
Pager 253-305-1189
MULTICARE CLINIC ONLY
LYMPHOMA-DLBCL
Phase III Randomized Study of R-CHOP v Dose-Adjusted Epoch-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas.
LYMPHOMA
S1106
A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients < 65 Years of Age with Previously Untreated Mantle Cell Lymphoma.
S0816
A Phase II Trial of Response-Adapted Therapy Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging.
MELANOMA
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-risk Melanoma.
NEUROPATHY PREVENTION
(Neurotoxicity Prevention)
A Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium in Two Different Versions to Prevent Oxaliplatin-Induced Sensory Neurotoxicity.